참조하세요. 무시되어온 질병에 대한 약품[개발을 위한] 이니셔티브(Drugs for Neglected Diseases Initiative)몇일전에 소개한 DNDi의 지적재산권 정책이 있어 소개합니다. 대충 보면최대한 공공재로 개발할 것이고, 환자들이 지불할 수 있을 정도를 보장한다.(싸게 만들겠다는 뜻)그리고 지적재산권 소유자와 협상을 벌여 환자들의 의약품에 접근을용이하게 하겠다. 는 내용인 듯합니다. http://www.accessmed-msf.org/upload/ReportsandPublications/19220031120226/DNDi.pdf위에 link되어 있는 글의 8page에 Legal and regulatory issues: DNDi will give serious consideration toIntellectual Property Rights (IPR) issues when deciding on projects,and adhere to drug regulations. * IPR issues: DNDi will develop an IPR policy with the followingimperatives in mind: to develop drugs as public goods wheneverpossible and ensure that these are affordable to patients who needthem. The policy will also consider the fact that its outputs areunlikely to have any commercial value and that R&D agreements willoften be made with public sector entities. DNDi will negotiatewith IPR owners to obtain the best possible conditions under whichdrugs can be made accessible to patients.이와 관련해서 MSF(http://www.accessmed-msf.org/index.asp)와 관련해서 참조하시고, MSF의 지적재산권 정책은http://www.accessmed-msf.org/campaign/faq.shtm31. Is MSF against patents?MSF does not oppose patents. Nor does MSF advocate forabolishing the patent system. But protecting human life musttake precedence over protecting intellectual property. Theimbalance that exists between the sanctity of patents and thehealth of people today must be corrected.MSF supports measures such as compulsory licensing, parallelimports, and mechanisms to accelerate the introduction ofgenerics, to help counter the adverse effects of patentprotection on public health in developing countries. MSFbelieves that these measures are possible under currentinternational WTO rules. However, should continued practisedemonstrate that the so-called safeguards of current trade rulesdon’t work, MSF will advocate for a full revision of the TRIPSagreement입니다. 자료 참조 사이트 : http://www.oekonux.org첨부 파일과거 URLhttp://www.ipleft.or.kr/bbs/view.php?board=ipleft_5&id=202